Enhertu still,not on pbs 2023
Just caught channel,7 news last night about ms Sarah Lee and her battle with stage 4. She has it in her bones and liver and was given six months to,live originally . It’s costing her family $12000 e...
Forum Discussion
Thanks @noosa_blue150 and @arpie
Enhertu first went to the Pharmaceutical Benefits Advisory Committee (PBAC) in July last year and it was not recommended to be listed on the PBS. AstraZeneca re-applied late 2022 and the decision was published by the PBAC on Friday. The PBAC deferred making a recommendation for Enhertu noting that further consultation with the sponsor regarding the cost-effectiveness would be required, along with revised financial estimates.
The decision can be found at:
BCNA continues to advocate to both AstraZeneca and the PBAC for Enhertu to be listed on the PBS to ensure equity of access to this treatment that has been shown to improve progression-free survival for people diagnosed with human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer.
A Patient Access Program (PAP) which provides free access to Enhertu for those eligible is available. Those who want more information or who think they might be eligible should contact their treating teams and/or oncologists. You cannot access the PAP yourself and must go through your oncologist.